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 ORIGINAL ARTICLE 
 Primary care physicians ’ adoption of new drugs is not associated 
with their clinical interests: A pharmacoepidemiologic study 
 TORBEN  DYBDAHL 1 ,  JENS  S Ø NDERGAARD 1 ,  JAKOB  KRAGSTRUP 1 ,  
IVAR S Ø NB Ø  KRISTIANSEN 1,2  &  MORTEN  ANDERSEN 1 
 1 Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, 
and  2 Institute of Health Management and Health Economics, University of Oslo, Norway 
 Abstract 
 Objectives. Increasing drug expenditures call for better understanding of the reasons behind individual general practitioners ’ 
(GPs ’ ) prescribing decisions. The aim was to analyse associations between GPs ’ clinical interests and their preference for 
new drugs.  Design. Historical cohort study using population-based prescription data and data collected by postal question-
naire.  Setting and subjects. A total of 68 single-handed GPs in the County of Funen, Denmark.  Main outcome measures. GPs ’ 
preferences for two new (2004) drug groups (selective cyclo-oxygenase-2 inhibitors and angiotensin-II antagonists) were 
analysed. The preference was defi ned as the percentage of patients receiving a new drug among fi rst-time users of either 
the new drug or an older alternative. The GPs ’ preference proportion was modelled using linear regression analysis. Data 
from a questionnaire on GPs ’ interest in corresponding clinical areas (musculoskeletal diseases and hypertension, respec-
tively), continuing medical education (CME) activities, and previous employment were the independent variables.  Results . 
The adjusted mean difference in preference for new drugs between GPs with high and low interest in each of the two 
clinical areas was 0.4% (95% CI  – 2.0% to 2.8%), and  – 2.2% ( – 15.0% to 10.7%), respectively. Only current CME activi-
ties in the area of hypertension were signifi cantly associated with GPs ’ preference for new drugs (adjusted mean difference 
17.9% (95% CI 5.8% to 30.0%).  Conclusion . No clear association between GPs ’ self-rated clinical interest and their 
prescribing of new drugs was found. 
 Key Words:  Drug utilization ,  general practice ,  pharmacoepidemiology ,  questionnaires 
 General practitioners ’ (GPs ’ ) prescribing of new drugs 
may have a considerable impact on health care expen-
ditures and quality of care [1,2]. While some new drugs 
represent important therapeutic improvements, many 
are not clearly superior to older and less expensive alter-
natives [3,4]. Often interventions have been launched 
in order to optimize physicians ’ choice among new and 
old therapeutic alternatives. However, randomized con-
trolled trials evaluating interventions targeting inappro-
priate prescribing have only rarely demonstrated an 
impact [4 – 6]. Effective interventions should be based 
on comprehensive insight into the mechanisms that 
infl uence GPs ’ choice of drug [7,8]. Traditional interven-
tion strategies, such as the dissemination of guidelines, 
address all physicians. Ideally, they should be directed at 
those GPs who are  “ in most need ” of being infl uenced, 
but knowledge of key characteristics associated with 
prescribing of new drugs is currently limited [9,10]. For 
example, a GP ’ s willingness to prescribe new drugs in 
one therapeutic group seems unrelated to previous pre-
scribing of the same group and also unrelated to the use 
of new drugs in other therapeutic drug groups [11,12]. 
 Since previous studies have failed to explain suffi -
ciently how and why physicians prescribe new drugs as 
they do, we suggest exploring more personal physician 
characteristics. It has been demonstrated that there are 
no or only weak associations between adoption of 
new drugs and the physicians ’ age and sex [13 – 16], 
hence other explanations should be sought. It has been 
hypothesized that GPs are inclined to prescribe new 
drugs in clinical areas in which they have a clinical 
interest [17 – 19]. Therefore, we aimed to analyse asso-
ciations between GPs ’ clinical interests and their 
preference for new drugs. 
Scandinavian Journal of Primary Health Care, 2011; 29: 117–121
ISSN 0281-3432 print/ISSN 1502-7724 online © 2011 Informa Healthcare
DOI: 10.3109/02813432.2011.570024
118 T. Dybdahl et al.
 Material and methods 
 This study was carried out in the Danish County of 
Funen ( ∼ 470 000 inhabitants) in 2004 and com-
prised data from a mailed questionnaire to GPs and 
from a prescription register. We chose to study pre-
scribing in two clinical areas: musculoskeletal dis-
eases and hypertension. As new drugs we included 
the class of selective cyclo-oxygenase-2 (COX-2) 
inhibitors and angiotensin-II antagonists (AT-II) 
(Table I). COX-2 inhibitors selectively inhibit cyclo-
oxygenase-2 and it was believed that these drugs 
would be effective therapy for painful conditions 
and in contrast to the traditional non-steroidal anti-
infl ammatory drugs (NSAIDs) would prove safer 
for the gastrointestinal (GI) tract by  “ sparing ” the 
COX-1 inhibition of protective prostaglandins. 
AT-IIs selectively block the angiotensin II receptor in 
contrast to the older alternative, the ACE inhibitors, 
that work earlier in the cascade and often have cough 
as a side effect. 
 The questionnaire 
 In December 2004, we sent a questionnaire focused 
on clinical interests to all GPs in the county (n   326). 
The questionnaire was part of a survey of GPs ’ 
demands and preferences for continuing medical 
education (CME). It was sent by mail together with 
a covering letter explaining the survey briefl y but not 
disclosing that the data would also be used to study 
adoption of new drugs. A prepaid reply envelope 
was enclosed. Non-responders were followed up 
after two and fi ve weeks. The questionnaire had been 
pilot tested with GPs in another county (County of 
Northern Jutland) and minor linguistic modifi ca-
tions were subsequently made. For each clinical area, 
the GPs were asked to indicate their level of clinical 
interest on a four-grade rating scale (from 1   very 
low to 4   very high) in musculoskeletal diseases and 
hypertension. The doctors were also asked to indi-
cate on a scale from 1 to 4 their perceived need for 
CME and to indicate current CME activities defi ned 
as whether in 2004 they had attended CME activities 
relevant to the clinical area or whether they planned 
to attend any in 2005. Finally, they were asked to 
indicate whether, prior to becoming a GP, they had 
been employed in hospital departments of cardiology 
and rheumatology. As an incentive to answer the 
questionnaire, all GPs participated in a lottery where 
the prizes comprised minor diagnostic equipments. 
 Databases 
 The Odense University Pharmacoepidemiologic Data-
base (OPED) comprises information on all prescrip-
tions redeemed at pharmacies in the County of 
Funen since 1992 [20]. Information includes date of 
redemption, the identity of the prescribing unit (gen-
eral practice, specialist, or hospital department), the 
patient ’ s identity, age, and gender, the brand, the 
Anatomical Therapeutic Chemical classifi cation code, 
and the quantity of the drug prescribed. 
 The Danish healthcare system is a tax-funded 
state system following the principle of universal, 
free, and equal access to healthcare services from 
hospitals and physicians outside hospitals [1]. Most 
drugs are partly reimbursed by the national health 
services (NHS) and the GPs can freely prescribe 
any of the studied drugs. Approximately 97% of the 
Danish population is listed with a GP and the NHS 
keeps records of the patients ’ identity, age, and gen-
der. The Danish Data Protection Agency approved 
the study. According to the Regional Research Ethics 
 Table I. Clinical areas studied and corresponding new and 
old drugs. 
Clinical area New drugs Old drug alternatives
Musculoskeletal 
diseases
Selective 
cyclo-
oxygenase-2 
inhibitors: 
celecoxib, 
etoricoxib, 
rofecoxib
Reimbursement 
date:
5 December 1994
Other non-steroidal 
anti-infl ammatory 
drugs: aceclofenac, 
dexibuprofen, 
diclofenac, etodolac, 
fl urbiprofen, ibuprofen, 
indomethacin, 
ketoprofen, ketorolac, 
lornoxicam, meloxicam, 
nabumetone, naproxen, 
phenylbutazone, 
piroxicam, sulindac, 
tenoxicam, tiaprofenic 
acid, tolfenomic acid
Hypertension Angiotensin-II 
receptor 
antagonists: 
candesartan, 
eprosartan, 
irbesartan, 
losartan, 
telmisartan, 
valsartan
Reimbursement 
date 
24 January 2000
Angiotensin-converting 
enzyme inhibitors: 
captopril, benazepril, 
enalapril, fosinopril, 
lisinopril, moexipril, 
perindopril, quinapril, 
ramipril, trandolapril
 General practitioners ’ (GPs ’ ) adoption of new 
drugs may infl uence health care quality and 
expenses. 
 Contrary to our hypothesis we found no  •
association between physicians ’ self-rated 
clinical interests and their prescribing of 
new drugs. 
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Committee, no ethical approval is necessary for this 
kind of register study. 
 Variables 
 For GPs working in group practices, the OPED can-
not identify the individual physician ’ s prescribing. 
Therefore, only data for GPs in single-handed prac-
tices were included in this study. For each clinical 
area, we quantifi ed each GP ’ s preference for new 
drugs in 2004 by the preference proportion. This was 
defi ned as the percentage of patients receiving a new 
drug within the respective class among fi rst-time 
users of either the new or an old drug (see Table I). 
First-time (incident) users were patients who had 
purchased neither a new nor an old drug during the 
365 days preceding their fi rst purchase in the study 
period. We standardized the preference proportion 
according to age and sex by means of direct stan-
dardization to the total population of users of new 
and old drugs. 
 Analyses 
 For each drug group, we modelled the preference 
proportion as a function of GPs ’ clinical interest in 
the corresponding clinical area (i.e. the group of 
selective COX-2 inhibitors and the clinical area mus-
culoskeletal diseases) using linear regression. 
 First, we undertook univariate regression analysis 
using the independent variable self-rated clinical inter-
est dichotomized into GPs with  “ low clinical interest ” 
(scores 1 and 2) and  “ high clinical interest ” (scores 3 
and 4). With respect to clinical interest in musculosk-
eletal diseases, only six GPs fell into the low interest 
group. Here, the lowest three levels (scores 1 – 3) were 
combined in the analysis. The regression coeffi cient of 
the dichotomized interest variable corresponds to the 
mean difference in preference proportion between the 
two  “ interest groups ” . Since perceived need for CME, 
current CME activities, and previous hospital employ-
ment may also infl uence GPs ’ choice of drugs, these 
were included in the analyses and the adjusted mean 
difference calculated using multivariate regression. 
Finally, we repeated the analyses using self-rated clin-
ical interest and perceived need for CME as continu-
ous variables (from 1 to 4). 
 Stata version 8.2 was used for statistical analyses. 
P-values of less than 0.05 were considered statistically 
signifi cant. 
 Results 
 There were 95 single-handed practitioners. Among 
these, 18 did not respond and nine declined partici-
pation. This left 68 GPs (72%) for analyses. The 
GPs ’ age, gender, mean prescribing rates, and varia-
tion index (defi ned as the ratio between the 90% and 
the 10% percentiles) were similar among responders 
and non-responders. Table II gives the distribution 
of answers to the questionnaire. 
 There was no statistically signifi cant association 
between GPs ’ self-reported  “ clinical interest ” and 
their preference for new drugs in the same clinical 
area for either of the two drug groups (Table III). This 
was the case when using univariate analysis and after 
adjustment for  “ perceived need for CME ” ,  “ CME 
activities “ , and  “ previous hospital employment ” . 
 Among the four independent variables, only 
 “ CME activities ” was statistically signifi cantly asso-
ciated with GPs ’ preference for new drugs and the 
association was signifi cant only for the clinical area 
hypertension (and the prescribing of angiotensin-II 
antagonists) (see Table III). The adjusted mean 
difference was 17.9 (95% CI: 5.8% to 30.0%). 
 Discussion 
 Little, if any, of the variation in the GPs ’ preference 
for new drugs could be attributed to the level of their 
 Table II. Distribution of the answers to the questionnaire: Actual numbers (percentage in parentheses). 
Variables Clinical area Very high High Low Very low
Self-rated clinical interest Musculoskeletal diseases 19 (27) 42 (62) 6 (9) 1 (1)
Hypertension 11 (16) 40 (59) 17 (25) 0 (0)
Perceived need for continuing 
medical education
Musculoskeletal diseases 2 (3) 37 (54) 24 (35) 2 (3)
Hypertension 1 (1) 12 (18) 46 (68) 4 (6)
Yes No
Current continuing medical 
education activities
Musculoskeletal diseases 44 (65) 24 (35)
Hypertension 46 (68) 22 (32)
Previous hospital employment Rheumatology 15 (22) 53 (78)
Cardiology 15 (22) 53 (78)
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 Table III. General practitioners ’ preference for two new drug groups (n   68) in corresponding clinical areas, quantifi ed 
by the preference proportion (PP).  
Clinical area
Musculoskeletal diseases Hypertension
Independent variables % %
Self-rated clinical interest Low (mean PP (IQR))
High (mean PP (IQR))
5.1 (2.3 – 7.4)
5.9 (2.6 – 8.2)
27.6 (6.2 – 33.6)
26.3 (9.0 – 36.5)
Mean difference (95% CI)
Adjusted 1 mean difference (95% CI)
0.8 ( – 1.5 – 3.0)
0.4 ( – 2.0 – 2.8)
 – 1.3 ( – 14.7 – 12.1)
 – 2.2 ( – 15.0 – 10.7)
Perceived need for continuing 
medical education
Low (mean PP (IQR))
High (mean PP (IQR))
5.4 (1.7 – 8.7)
5.3 (2.4 – 6.8)
26.8 (6.9 – 36.5)
25.9 (8.7 – 37.6)
Mean difference (95% CI)
Adjusted 1 mean difference (95% CI)
 – 0.1 ( – 2.1 – 2.0)
 – 0.2 ( – 2.3 – 1.9)
 – 0.9 ( – 16.0 – 14.3)
 – 0.3 ( – 14.9 – 10.7)
Current continuing medical 
education activities
No (mean PP (IQR))
Yes (mean PP (IQR))
4.4 (2.3 – 6.0)
5.9 (2.0 – 8.8)
14.2 (0.0 – 19.2)
32.4 (10.9 – 51.9)
Mean difference (95% CI)
Adjusted 1 mean difference (95% CI)
1.5 ( – 0.6 – 3.6)
1.6 ( – 0.5 – 3.8)
18.2 (6.5 – 29.9) 2 
17.9 (5.8 – 30.0) 2 
Previous hospital employment No (mean PP (IQR))
Yes (mean PP (IQR))
5.6 (2.3 – 7.7)
4.5 (1.5 – 6.8)
25.3 (6.7 – 35.8)
31.4 (9.0 – 54.1)
Mean difference (95% CI)
Adjusted 1 mean difference (95% CI)
 – 1.1 ( – 3.6 – 1.3)
 – 1.4 ( – 4.0 – 1.2)
6.1 ( – 7.7 – 20.0)
3.5 ( – 9.9 – 16.9)
 Notes:  1 Linear regression analysis;  2 p   0.05. 
clinical interests. Although their preferences for new 
drugs appeared to be associated with CME activities 
in some clinical areas, the association was not 
consistent across both classes of drugs. 
 Recall bias when GPs report on CME activities 
and previous hospital employment could be a serious 
concern. However, because GPs only had to remem-
ber CME activities over the last year and only had 
to remember in what type of department they had 
been employed (not the exact place and duration of 
employment) recall bias is unlikely to have infl u-
enced the results highly. A major strength of our 
study is the use of reliable, population-based data on 
GPs ’ prescribing [20], which enabled us to accu-
rately measure GPs ’ actual prescribing patterns. In 
Denmark, all prescriptions are registered electroni-
cally and health care providers and pharmacists 
have an economic incentive to provide accurate data. 
Non-redemption of prescriptions (primary non-
compliance) may reduce the data accuracy, but this 
seems to be a minor problem in Denmark [21]. 
 Statistical power is an important issue when stud-
ies do not detect signifi cant association as proposed 
by the hypothesis. The narrow confi dence intervals 
(see Table III) in our study indicate, however, that 
we had suffi cient power to detect relevant associa-
tions. It is noteworthy that among physicians with 
low as well as among physicians with high interest in 
a clinical area, their preferences for new drugs varied 
considerably as indicated by the wide inter-quartile 
ranges (Table III). This variation indicates that there 
may be other factors infl uencing GPs ’ choice of drug, 
thus making it diffi cult to detect a signifi cant effect 
of clinical interest per se. 
 The decline in COX-2 prescribing rates after 
reports on cardiovascular toxicity is proof that a single 
issue concerning drug safety may lead to great changes 
during a short period of time. More generally, however, 
insight into what factors affect physicians ’ prescribing 
is still lacking. GPs ’ choice of prescription drugs may 
be infl uenced by patient, physician, and drug char-
acteristics. Patient characteristics may include aspects 
such as medical condition including diagnosis and 
sociodemographic variables such as age, sex, and 
social class [22]. Doctor characteristics may include 
such aspects as age, sex, attitude towards prescribing 
of new drugs [19,22], practice style and setting 
[18,23,24], hospital-initiated prescribing [25], patient 
pressure [26], pharmaceutical contacts [18], and 
other attempts at intervention (27). Drug character-
istics may be related to price, potential side effects, 
perceived effectiveness, long-term effects, and likely 
benefi ts of the drug [17 – 19]. With so many different 
factors likely to infl uence the GPs ’ drug choice, it is 
conceivable that each factor will have only a moder-
ate impact, which may explain the lack of positive 
fi ndings in this study. This may particularly be so 
because interaction between the various factors 
may hide the impact of each single factor. GPs ’ 
choice of prescription drugs is the result of a 
complex decision process with an array of potential 
infl uences. In other words, we need high-powered 
studies with a high number of explanatory variables. 
In order to better tailor interventions, we still lack a 
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better understandng of the mechanisms underlying 
drug choice. 
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